PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 3673588-1 1987 A selective zymosan-induced release of lysozyme from freshly prepared human blood granulocytes and monocytes was inhibited by indomethacin, sulindac, piroxicam and ibuprofen. Zymosan 12-19 lysozyme Homo sapiens 39-47 3710563-2 1986 Stimulated release of lysozyme (from specific granules and azurophil granules) and beta-glucuronidase (from azurophil granules) in the presence of both FMLP and serum-activated zymosan was markedly reduced in patients with actively spreading guttate psoriatic lesions, in whom relapse of lesions lasted for less than 1 month and papules involved about 13-25% of skin surface. Zymosan 177-184 lysozyme Homo sapiens 22-30 3570357-7 1987 Examination of lysosomal enzyme release showed that sCM enhanced the release of lysozyme and beta-glucuronidase induced by either FMLP/cytochalasin B or zymosan. Zymosan 153-160 lysozyme Homo sapiens 80-88 2421757-5 1986 Similarly, the release of the lysosomal enzymes, beta-glucuronidase and lysozyme, from neutrophils of the WAS patient in response to serum treated zymosan (Zx), f-met peptide, and A23187 was not significantly different from that of his parents and 13 normal donors. Zymosan 147-154 lysozyme Homo sapiens 72-80 2982389-1 1985 Myeloperoxidase (MPO)-deficient neutrophils (PMN) released considerably more beta-glucuronidase, lysozyme and vitamin B12-binding activities, when exposed to opsonized zymosan (STZ), than the normal counterpart. Zymosan 168-175 lysozyme Homo sapiens 97-105 3804532-1 1986 Doxycycline inhibited the release of lysozyme from human granulocytes and monocytes exposed to non-opsonized zymosan particles. Zymosan 109-116 lysozyme Homo sapiens 37-45 3804532-5 1986 The divalent cation chelator, EDTA, also reduced the release of lysozyme from leukocytes exposed to non-opsonized zymosan. Zymosan 114-121 lysozyme Homo sapiens 64-72 9743814-9 1998 CS and its fractions inhibit the directional chemotaxis induced by zymosan-activated serum, are able to decrease the phagocytosis and the release of lysozyme induced by zymosan and to protect the plasma membrane from oxygen reactive species. Zymosan 169-176 lysozyme Homo sapiens 149-157 6327867-1 1984 When exposed to zymosan or latex particles or heat-inactivated staphylococci, freshly prepared human blood monocytes and granulocytes rapidly released a large fraction of their lysozyme content. Zymosan 16-23 lysozyme Homo sapiens 177-185 8871837-8 1996 Neutrophil stimulation by serum-treated zymosan, at the concentration of 0.3 mg/ml, induced a release of lysozyme that was significantly higher in patients with RA when compared to control subjects (p < 0.05), whereas zymosan-activated beta-glucuronidase secretion was similar in the two donor populations. Zymosan 40-47 lysozyme Homo sapiens 105-113 8871837-8 1996 Neutrophil stimulation by serum-treated zymosan, at the concentration of 0.3 mg/ml, induced a release of lysozyme that was significantly higher in patients with RA when compared to control subjects (p < 0.05), whereas zymosan-activated beta-glucuronidase secretion was similar in the two donor populations. Zymosan 221-228 lysozyme Homo sapiens 105-113